

3 November 2023

ASX ANNOUNCEMENT

Largest US Private Payor Updates Medical Policy for BIS

ImpediMed Limited (ASX:IPD) today announces that UnitedHealthcare, the largest Private Payor in the U.S., updated its Commercial and Individual Exchange Medical Policy Omnibus Codes policy stating that *Bioimpedance Spectroscopy (BIS) for Lymphedema Assessment (CPT Code 93702)* no longer requires clinical review.

Key Points:

- UnitedHealthcare (“UHC”) published Policy Number 2024T0535QQQ.
- The policy was updated to state that CPT code 93702 no longer requires clinical review.
- The policy has an effective date of 1 January 2024.
- UHC’s previous policy, Policy Number 2023T0535PPP, stated that CPT code 93702 for BIS and extracellular fluid analysis for lymphedema assessment(s) was “unproven and not medically necessary.”
 - This is what the Company has historically referred to as the experimental list.
- The updated policy has removed CPT code 93702 from the code section where it was previously stated as “unproven”.
 - This is what the Company refers to as silent coverage.

A link to the policy can be found here:

<https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/commercial/omnibus-codes-01012024.pdf>

“This is a very exciting step for patients at risk of lymphoedema. We expect this change to mean that we will have silent coverage from UnitedHealthcare, when the policy goes into effect in January 2024. With this change, UnitedHealthcare will be the second Top 5 national payor to cover SOZO testing for lymphoedema. Cigna was the first”, stated Rick Valencia, Managing Director and CEO of ImpediMed.

“Silent coverage is not uncommon. U.S. Medicare and 27 other Private Payors currently cover our technology through silent coverage. With the addition of UnitedHealthcare, we will achieve six (6) states at Critical Mass¹ to start the calendar year”, he continued.

About UnitedHealthcare and UnitedHealth Group

UnitedHealthcare is the health benefits business of UnitedHealth Group, a health care and well-being company working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences.² UnitedHealthcare is one of the largest single health carriers in the U.S., serving approximately 47 million members across the U.S.³

Approved for release by the Managing Director & CEO, Richard Valencia.

¹ Critical mass refers to >80% covered lives in a state, which is required to streamline health system workflows and accelerate sales efforts in a state. The Company has previously announced two states at Critical Mass: Michigan and Alabama.

² <https://www.uhc.com/about-us>

³ <https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2023/UNH-Q3-2023-Release.pdf>

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only